Clinical Decision Support Tool for Infliximab in Crohn's Disease

Clin Gastroenterol Hepatol. 2022 May;20(5):e1192-e1195. doi: 10.1016/j.cgh.2021.06.037. Epub 2021 Jun 30.


Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clinical decision support tools for achieving clinical remission (CREM) with vedolizumab and ustekinumab in CD.1-4 We now aim to develop a clinical decision support tool for infliximab in CD.

Trial registration: NCT00094458 NCT02096861.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Crohn Disease* / drug therapy
  • Decision Support Systems, Clinical*
  • Humans
  • Infliximab / therapeutic use
  • Ustekinumab / therapeutic use


  • Infliximab
  • Ustekinumab

Associated data